In this review, we discuss several important issues concerning the discovery of protein biomarkers for complex human diseases, with a focus on type 1 diabetes. Serum or plasma is the first choice of specimen due to its richness in biological information and relatively easy availability. It is a challenging task to comprehensively characterize the serum/plasma proteome because of the large dynamic range of protein concentration. Therefore, sample pretreatment is required in order to explore the low- to medium-abundance proteins contained in serum/ plasma. In this regard, enrichment of low-abundance proteins using random hexapeptide library beads has distinct advantages over the traditional immune-depletion methods, including higher efficiency, higher binding capacity, and lower cost. In-depth mining of serum/plasma proteome using different separation techniques have also been evaluated and are discussed in this review. Overall, the shotgun proteomics—multidimensional separation of digested peptides followed by mass spectrometry analysis—is highly Efficient and therefore has become a preferred method for protein biomarker discovery.
JacobsJMAdkinsJNQianWJLiuTShenYCampDG2ndSmithRD. Utilizing human blood plasma for proteomic biomarker discovery. J Proteome Res. 2005; 4 (4): 1073–85.
2.
SimpsonRJBernhardOKGreeningDWMoritzRL. Proteomics-driven cancer biomarker discovery: looking to the future. Curr Opin Chem Biol. 2008; 12 (1): 72–7.
3.
LiFFangYXiaoZQChenZC. Clinical proteomics: the application of proteomics in the research of clinical medicine. Prog Biochem Biophys. 2006; 33 (1): 5–9.
4.
PurohitSSheJX. Biomarkers for type 1 diabetes. Int J Clin Exp Med. 2008; 1 (2): 98–116.
5.
SosenkoJMKrischerJPPalmerJPMahonJCowieCGreenbaumCJCuthbertsonDLachinJMSkylerJS, Diabetes Prevention Trial-Type 1 Study Group. A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1. Diabetes Care. 2008; 31 (3): 528–33.
6.
MauryaPMeleadyPDowlingPClynesM. Proteomic approaches for serum biomarker discovery in cancer. Anticancer Res. 2007; 27 (3A): 1247–55.
7.
OldWMMeyer-ArendtKAveline-WolfLPierceKGMendozaASevinskyJRResingKAAhnNG. Comparison of label-free methods for quantifying human proteins by shotgun proteomics. Mol Cell Proteomics. 2005; 4 (10): 1487–502.
8.
AsaraJMChristofkHRFreimarkLMCantleyLC. A label-free quantification method by MS/MS TIC compared to SILAC and spectral counting in a proteomics screen. Proteomics. 2008; 8 (5): 994–9.
9.
AndersonL. Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J Physiol. 2005; 563 (Pt 1): 23–60.
10.
JacobsJMAdkinsJNQianWJLiuTShenYCampDG2ndSmithRD. Utilizing human blood plasma for proteomic biomarker discovery. J Proteome Res. 2005; 4 (4): 1073–85.
11.
GongYLiXYangBYingWLiDZhangYDaiSCaiYWangJHeFQianX. Different immunoaffinity fractionation strategies to characterize the human plasma proteome. J Proteome Res. 2006; 5 (6): 1379–87.
12.
RighettiPGBoschettiELomasLCitterioA. Protein Equalizer Technology: the quest for a “democratic proteome.”Proteomics. 2006; 6 (14): 3980–92.
13.
BrandJHaslbergerTZolgWPestlinGPalmeS. Depletion efficiency and recovery of trace markers from a multiparameter immunodepletion column. Proteomics. 2006; 6 (11): 3236–42.
14.
EchanLATangHYAli-KhanNLeeKSpeicherDW. Depletion of multiple high-abundance proteins improves protein profling capacities of human serum and plasma. Proteomics. 2005; 5 (13): 3292–303.
15.
SennelsLSalekMLomasLBoschettiERighettiPGRappsilberJ. Proteomic analysis of human blood serum using peptide library beads. J Proteome Res. 2007; 6 (10): 4055–62.
16.
BoschettiELomasLCitterioARighettiPG. Romancing the “hidden proteome,” Anno Domini two zero zero seven. J Chromatogr A. 2007; 1153 (1–2): 277–90.
17.
EliasJEHaasWFahertyBKGygiSP. Comparative evaluation of mass spectrometry platforms used in large-scale proteomics investigations. Nat Methods. 2005; 2 (9): 667–75.
18.
WilkinsMRAppelRDVan EykJEChungMCGörgAHeckerMHuberLALangenHLinkAJPaikYKPattersonSDPenningtonSRRabilloudTSimpsonRJWeissWDunnMJ. Guidelines for the next 10 years of proteomics. Proteomics. 2006; 6 (1): 4–8.
19.
LiuTQianWJMottazHMGritsenkoMANorbeckADMooreRJPurvineSOCampDG2ndSmithRD. Evaluation of multiprotein immunoaffinity subtraction for plasma proteomics and candidate biomarker discovery using mass spectrometry. Mol Cell Proteomics. 2006; 5 (11): 2167–74.
20.
YocumAKYuKOeTBlairIA. Effect of immunoaffinity depletion of human serum during proteomic investigations. J Proteome Res. 2005; 4 (5): 1722–31.
21.
SihlbomCKanmertIBahrHDavidssonP. Evaluation of the Combination of Bead Technology with SELDI-TOF-MS and 2-D DIGE for detection of plasma proteins. J Proteome Res. 2008; 7 (9): 4191–8.
22.
DwivediRCKrokhinOVCortensJPWilkinsJA. Assessment of the reproducibility of random hexapeptide peptide library-based protein normalization. J Proteome Res. 2010; 9 (2): 1144–9.
WangHHanashS. Intact-protein based sample preparation strategies for proteome analysis in combination with mass spectrometry. Mass Spectrom Rev. 2005; 24 (3): 413–26.
25.
HornAKreuschSBublitzRHoppeHCummeGASchulzeMMooreTDitzeGRhodeH. Multidimensional proteomics of human serum using parallel chromatography of native constituents and microplate technology. Proteomics. 2006; 6 (2): 559–70.
26.
AssiddiqBFWilliamsonJCSnijdersAPCookKDickmanMJ. Multidimensional liquid phase protein separations in conjunction with stable isotope labelling for quantitative proteomics. Proteomics. 2007; 7 (21): 3826–34.
27.
WangHChang-WongTTangHYSpeicherDW. Comparison of extensive protein fractionation and repetitive LC-MS/MS analyses on depth of analysis for complex proteomes. J Proteome Res. 2010; 9 (2): 1032–40.
28.
FangYRobinsonDPFosterLJ. Quantitative analysis of proteome coverage and recovery rates for upstream fractionation methods in proteomics. J Proteome Res. 2010; 9 (4): 1902–12.
29.
SundstenTEberhardsonMGöranssonMBergstenP. The use of proteomics in identifying differentially expressed serum proteins in humans with type 2 diabetes. Proteome Sci. 2006; 4: 22.
30.
KimHJChoEHYooJHKimPKShinJSKimMRKimCW. Proteome analysis of serum from type 2 diabetics with nephropathy. J Proteome Res. 2007; 6 (2): 735–43.
31.
ChoWCYipTTChungWSLeungAWChengCHYueKK. Differential expression of proteins in kidney, eye, aorta, and serum of diabetic and non-diabetic rats. J Cell Biochem. 2006; 99 (1): 256–68.
32.
RiazSAlamSSAkhtarMW. Proteomic identification of human serum biomarkers in diabetes mellitus type 2. J Pharm Biomed Anal. 2010; 51 (5): 1103–7.
33.
PurohitSPodolskyRSchatzDMuirAHopkinsDHuangYHSheJX. Assessing the utility of SELDI-TOF and model averaging for serum proteomic biomarker discovery. Proteomics. 2006; 6 (24): 6405–15.
